4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -141,696 | -68,760 | -140,109 | -159,506 | -102,630 |
| Depreciation Amortization | 425 | 135 | -40 | -109 | -216 |
| Accounts payable and accrued liabilities | -525 | 3,533 | 6,773 | 2,477 | 4,314 |
| Other Working Capital | -8,854 | -4,751 | 6,172 | 3,417 | -1,582 |
| Other Operating Activity | 12,526 | 1,718 | 18,122 | 16,088 | 8,979 |
| Operating Cash Flow | $-138,124 | $-68,125 | $-109,082 | $-137,633 | $-91,135 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -55 | 11 | -536 | -606 | -697 |
| Purchase Of Investment | -95,555 | -33,519 | -442,821 | -264,721 | -249,480 |
| Sale Of Investment | 190,042 | 102,396 | 350,384 | 301,201 | 268,273 |
| Investing Cash Flow | $94,432 | $68,888 | $-92,973 | $35,874 | $18,096 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 53,823 | 11,484 | 19,420 | 978 | 862 |
| Other Financing Activity | 0 | 0 | 93,540 | 0 | 0 |
| Financing Cash Flow | $53,823 | $11,484 | $112,960 | $978 | $862 |
| Beginning Cash Position | 60,241 | 60,241 | 149,336 | 149,336 | 149,336 |
| End Cash Position | 70,372 | 72,488 | 60,241 | 48,555 | 77,159 |
| Net Cash Flow | $10,131 | $12,247 | $-89,095 | $-100,781 | $-72,177 |
| Free Cash Flow | |||||
| Operating Cash Flow | -138,124 | -68,125 | -109,082 | -137,633 | -91,135 |
| Capital Expenditure | -55 | 11 | -536 | -606 | -697 |
| Free Cash Flow | -138,179 | -68,114 | -109,618 | -138,239 | -91,832 |